WWP2-WWP1 ubiquitin ligase complex coordinated by PPM1G maintains the balance between cellular p73 and ΔNp73 levels

Molecular and Cellular Biology

Volumn 34, Issue 19, 2014, Pages 3754-3764

  Chaudhary, Neelam ^a   Maddika, Subbareddy ^a  

^a CENTRE FOR DNA FINGERPRINTING AND DIAGNOSTICS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CADMIUM CHLORIDE; CISPLATIN; PPM1G PROTEIN; PROTEIN P73; SHORT HAIRPIN RNA; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; WWP1 PROTEIN; WWP2 PROTEIN; DNA BINDING PROTEIN; ISOPROTEIN; NUCLEAR PROTEIN; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2C; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73; WWP1 PROTEIN, HUMAN; WWP2 PROTEIN, HUMAN;

APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CELL LEVEL; CELL STRESS; CONTROLLED STUDY; DELETION MUTANT; DIMERIZATION; DNA DAMAGE; DOWN REGULATION; FLOW CYTOMETRY; GEL FILTRATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETRY; OLIGOMERIZATION; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN STABILITY; RNA INTERFERENCE; UBIQUITINATION; UPREGULATION; GENE EXPRESSION REGULATION; HEK293 CELL LINE; HELA CELL LINE; METABOLISM; PROTEIN MULTIMERIZATION;

APOPTOSIS; CISPLATIN; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HEK293 CELLS; HELA CELLS; HUMANS; NUCLEAR PROTEINS; PHOSPHOPROTEIN PHOSPHATASES; PROTEIN ISOFORMS; PROTEIN MULTIMERIZATION; PROTEOLYSIS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84906952759     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00101-14     Document Type: Article

References (35)

1. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819. http://dx.doi.org/10.1016/S0092-8674(00)80540-1.
2. Al-Bahlani S, Fraser M, Wong AY, Sayan BS, Bergeron R, Melino G, Tsang BK. 2011. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism. Oncogene 30: 4219-4230. http://dx.doi.org/10.1038/onc.2011.134.
3. Jost CA, Marin MC, Kaelin WG, Jr. 1997. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389:191-194. http://dx.doi.org/10.1038/38298.
4. Zhu J, Jiang J, Zhou W, Chen X. 1998. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 58:5061- 5065.
5. Arrowsmith CH. 1999. Structure and function in the p53 family. Cell Death Differ. 6:1169-1173. http://dx.doi.org/10.1038/sj.cdd.4400619.
6. Araki D, Uzawa K, Watanabe T, Shiiba M, Miyakawa A, Yokoe H, Tanzawa H. 2002. Frequent allelic losses on the short arm of chromosome 1 and decreased expression of the p73 gene at 1p36.3 in squamous cell carcinoma of the oral cavity. Int. J. Oncol. 20:355-360. http://dx.doi.org /10.3892/ijo.20.2.355.
7. Ichimiya S, Nimura Y, Kageyama H, Takada N, Sunahara M, Shishikura T, Nakamura Y, Sakiyama S, Seki N, Ohira M, Kaneko Y, McKeon F, Caput D, Nakagawara A. 1999. p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene 18:1061-1066. http://dx.doi.org/10.1038/sj.onc.1202390.
8. Shan L, Yang Q, Nakamura Y, Nakamura M, Miyauchi A, Tsujimoto M, Nakatani Y, Wakasa K, Mori I, Kakudo K. 2001. Frequent loss of heterozygosity at 1p36.3 and p73 abnormality in parathyroid adenomas. Mod. Pathol. 14:273-278. http://dx.doi.org/10.1038/modpathol.3880302.
9. Shishikura T, Ichimiya S, Ozaki T, Nimura Y, Kageyama H, Nakamura Y, Sakiyama S, Miyauchi M, Yamamoto N, Suzuki M, Nakajima N, Nakagawara A. 1999. Mutational analysis of the p73 gene in human breast cancers. Int. J. Cancer 84:321-325. http://dx.doi.org/10.1002/(SICI)1097 -0215(19990621)84:3<321::AID-IJC21> 3.0.CO;2-S.
10. Ahomadegbe JC, Tourpin S, Kaghad M, Zelek L, Vayssade M, Mathieu MC, Rochard F, Spielmann M, Tursz T, Caput D, Riou G, Benard J. 2000. Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers. Oncogene 19:5413-5418. http://dx.doi.org/10.1038/sj.onc .1203914.
11. El-Naggar AK, Lai S, Clayman GL, Mims B, Lippman SM, Coombes M, Luna MA, Lozano G. 2001. p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. Carcinogenesis 22:729-735. http://dx.doi.org/10.1093/carcin/22.5.729.
12. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, Khan F, Itie-Youten A, Wakeham A, Tsao MS, Iovanna JL, Squire J, Jurisica I, Kaplan D, Melino G, Jurisicova A, Mak TW. 2008. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 22:2677-2691. http://dx.doi.org/10.1101/gad.1695308.
13. Melino G, Lu X, Gasco M, Crook T, Knight RA. 2003. Functional regulation of p73 and p63: development and cancer. Trends Biochem. Sci. 28:663-670. http://dx.doi.org/10.1016/j.tibs.2003.10.004.
14. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F, Hugli B, Graber HU, De Laurenzi V, Fey MF, Melino G, Tobler A. 2001. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 8:1213-1223. http://dx.doi.org/10.1038/sj.cdd .4400962.
15. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM. 2002. ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 196:765-780. http://dx.doi.org/10.1084/jem.20020179.
16. Stiewe T, Putzer BM. 2001. p73 in apoptosis. Apoptosis 6:447-452. http: //dx.doi.org/10.1023/A:1012433522902.
17. Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC, Vousden KH, Cesareni G, Melino G. 2005. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J. 24:836-848. http://dx.doi.org/10.1038/sj.emboj .7600444.
18. Muller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H, Oren M, Koch A, Tannapfel A, Stremmel W, Melino G, Krammer PH. 2005. TAp73/ΔNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ. 12:1564-1577. http://dx.doi.org/10.1038/sj.cdd.4401774.
19. Chen C, Matesic LE. 2007. The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev. 26:587-604. http://dx.doi.org/10.1007 /s10555-007-9091-x.
20. Li H, Zhang Z, Wang B, Zhang J, Zhao Y, Jin Y. 2007. Wwp2-mediated ubiquitination of the RNA polymerase II large subunit in mouse embryonic pluripotent stem cells. Mol. Cell. Biol. 27:5296-5305. http://dx.doi .org/10.1128/MCB.01667-06.
21. McDonald FJ, Western AH, McNeil JD, Thomas BC, Olson DR, Snyder PM. 2002. Ubiquitin-protein ligase WWP2 binds to and downregulates the epithelial Na+ channel. Am. J. Physiol. Renal Physiol. 283:F431-F436.
22. Xu HM, Liao B, Zhang QJ, Wang BB, Li H, Zhong XM, Sheng HZ, Zhao YX, Zhao YM, Jin Y. 2004. Wwp2, an E3 ubiquitin ligase that targets transcription factor Oct-4 for ubiquitination. J. Biol. Chem. 279: 23495-23503. http://dx.doi.org/10.1074/jbc.M400516200.
23. Maddika S, Kavela S, Rani N, Palicharla VR, Pokorny JL, Sarkaria JN, Chen J. 2011. WWP2 is an E3 ubiquitin ligase for PTEN. Nat. Cell Biol. 13:728-733. http://dx.doi.org/10.1038/ncb2240.
24. Chantry A. 2011. WWP2 ubiquitin ligase and its isoforms: new biological insight and promising disease targets. Cell Cycle 10:2437-2439. http://dx .doi.org/10.4161/cc.10.15.16874.
25. Maddika S, Chen J. 2009. Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase. Nat. Cell Biol. 11:409-419. http://dx.doi .org/10.1038/ncb1848.
26. Zhi X, Chen C. 2012. WWP1: a versatile ubiquitin E3 ligase in signaling and diseases. Cell. Mol. Life Sci. 69:1425-1434. http://dx.doi.org/10.1007 /s00018-011-0871-7.
27. Khoronenkova SV, Dianova II, Ternette N, Kessler BM, Parsons JL, Dianov GL. 2012. ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage. Mol. Cell 45:801-813. http://dx.doi.org/10.1016/j.molcel.2012.01.021.
28. Kimura H, Takizawa N, Allemand E, Hori T, Iborra FJ, Nozaki N, Muraki M, Hagiwara M, Krainer AR, Fukagawa T, Okawa K. 2006. A novel histone exchange factor, protein phosphatase 2Cγ, mediates the exchange and dephosphorylation of H2A-H2B. J. Cell Biol. 175:389-400. http://dx.doi.org/10.1083/jcb.200608001.
29. Pan C, Liu HD, Gong Z, Yu X, Hou XB, Xie DD, Zhu XB, Li HW, Tang JY, Xu YF, Yu JQ, Zhang LY, Fang H, Xiao KH, Chen YG, Wang JY, Pang Q, Chen W, Sun JP. 2013. Cadmium is a potent inhibitor of PPM phosphatases and targets the M1 binding site. Sci. Rep. 3:2333. http://dx .doi.org/10.1038/srep02333.
30. Urist M, Tanaka T, Poyurovsky MV, Prives C. 2004. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev. 18:3041-3054. http://dx.doi.org/10.1101/gad.1221004.
31. Sayan BS, Yang AL, Conforti F, Tucci P, Piro MC, Browne GJ, Agostini M, Bernardini S, Knight RA, Mak TW, Melino G. 2010. Differential control of TAp73 and ΔNp73 protein stability by the ring finger ubiquitin ligase PIR2. Proc. Natl. Acad. Sci. U. S. A. 107:12877-12882. http://dx.doi .org/10.1073/pnas.0911828107.
32. Hosoda M, Ozaki T, Miyazaki K, Hayashi S, Furuya K, Watanabe K, Nakagawa T, Hanamoto T, Todo S, Nakagawara A. 2005. UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination. Oncogene 24:7156-7169. http://dx.doi.org/10.1038/sj.onc.1208872.
33. Peschiaroli A, Scialpi F, Bernassola F, Pagano M, Melino G. 2009. The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73. Oncogene 28:3157-3166. http://dx.doi.org/10.1038/onc.2009.177.
34. Hock A, Vousden KH. 2010. Regulation of the p53 pathway by ubiquitin and related proteins. Int. J. Biochem. Cell Biol. 42:1618-1621. http://dx .doi.org/10.1016/j.biocel.2010.06.011.
35. Soond SM, Smith PG, Wahl L, Swingler TE, Clark IM, Hemmings AM, Chantry A. 2013. Novel WWP2 ubiquitin ligase isoforms as potential prognostic markers and molecular targets in cancer. Biochim. Biophys. Acta 1832:2127-2135. http://dx.doi.org/10.1016/j.bbadis.2013.08.001.